CBMG
Cellular Biomedicine Group, Inc.
Set alert
No live quote for CBMG yet.
- Open
- 19.74
- Prev close
- 19.75
- Mkt cap
- 384.69M
- Vol
- 169.29K
- Avg vol
- 94.04K
- EPS
- -2.83
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.73
- High
- 19.75
- Forward P/E
- -7.51
- Beta
- 1.21
- Short ratio
- 3.48
- Inst. own
- 33.84%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 18.91
- 200-d avg
- 18.44
- 1y target
- 19.00
Key statistics
- Market cap
- 384.69M
- Enterprise value
- 424.69M
- Trailing P/E
- 0.00
- Forward P/E
- -7.51
- PEG ratio
- 0.00
- Price / sales
- 1191.18
- Price / book
- 22.17
- EPS (TTM)
- -2.83
- Beta
- 1.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 322.95K
- Revenue growth
- 0.00%
- Free cash flow
- -17.59M
- Total cash
- 26.03M
- Total debt
- 66.39M
- Return on equity
- -129.91%
- Shares outstanding
- 19.48M
- Short % of float
- 3.22%
- 50-day average
- 18.91
- 200-day average
- 18.44
Analyst view
Consensus: hold
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 12, 2020 | Baird | down | Outperform | Neutral |
| Jul 12, 2020 | Baird | up | Neutral | Outperform |
| Mar 4, 2020 | BTIG Research | down | Buy | Neutral |
| Nov 11, 2019 | Baird | down | Outperform | Neutral |
| Sep 16, 2019 | BTIG | init | — | Buy |
| Jun 24, 2019 | Cantor Fitzgerald | init | — | Overweight |
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York. As of February 19, 2021, Cellular Biomedicine Group, Inc. was taken private.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cellbiomedgroup.com
News
- Stocks That Hit 52-Week Highs On Wednesday
- Stocks That Hit 52-Week Highs On Tuesday
- Stocks That Hit 52-Week Highs On Friday
- Stocks That Hit 52-Week Highs On Wednesday
- Benzinga's Top Upgrades, Downgrades For September 17, 2019
- 88 Biggest Movers From Yesterday
- 44 Biggest Movers From Yesterday
- 55 Biggest Movers From Yesterday
- 43 Stocks Moving In Wednesday's Mid-Day Session
Your note
Sign in to keep a note on CBMG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BELMONT TERRY | Director | Sale | Jun 14, 2015 | 0 |
| CAO WEI | Director | Sale | Feb 29, 2016 | 174,472 |
| CHAN ANDREW K | Officer | Stock Award(Grant) | Feb 18, 2021 | 0 |
| KLEIN NORMAN PAUL II | Director | Stock Award(Grant) | Feb 5, 2013 | 136,153 |
| LEUNG PAK TO | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 22, 2014 | 0 |
| LIU TONY | Chief Executive Officer | Stock Award(Grant) | Feb 18, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 4.51% | 878,324 | 16.14M | Dec 30, 2020 |
| Man Group PLC | 1.27% | 247,838 | 4.55M | Sep 29, 2020 |
| Candriam Luxembourg S.C.A. | 1.21% | 235,317 | 4.33M | Dec 30, 2020 |
| Hillhouse Capital Advisors Ltd. | 1.21% | 235,214 | 4.31M | Sep 29, 2020 |
| State Street Corporation | 1.17% | 228,070 | 4.18M | Sep 29, 2020 |
| Vanguard Group, Inc. (The) | 1.11% | 216,256 | 3.97M | Sep 29, 2020 |